Orexin agonists represent a promising new frontier in pharmaceutical development, potentially mirroring the success of GLP-1 drugs by treating narcolepsy and addressing broader conditions like depression and addiction. Beyond medical innovation, Japan’s startup ecosystem faces significant structural hurdles, including a shortage of risk-tolerant capital, low cultural prestige for entrepreneurship, and a tendency for firms to rush into premature IPOs. These factors have limited the country's production of billion-dollar unicorns compared to global peers. Meanwhile, procrastination functions as a form of self-regulatory failure with tangible consequences, including reduced annual earnings and poorer health outcomes. Research suggests that while no specific medication currently treats this behavior, physical exercise and mental contrasting techniques offer viable strategies for improving executive function and task initiation.
Sign in to continue reading, translating and more.
Open full episode in Podwise